AMSBIO offers a range of kits, media and reagents enabling development of food in a way that is not wasteful of our natural resources and is not detrimental to the environment or consumer health.
Recent advances in biotechnological methods have enabled the development of cultured meat - meat grown in a laboratory using stem cell technology that mimics the texture, flavor, and nutritional value of conventional meat. Cultured meat has the potential to be less resource intensive through the lessening of animal husbandry and slaughter leading to knock on…
Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development.
In this article, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, explores the potential of PDCs and their role in shaping the future of drug discovery.
In the pharma industry, it is widely acknowledged that drug target validation needs to be carried out more effectively. Drug discovery is…
Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients
Cambridge, Cambridgeshire (UK) and Cambridge, Massachusetts (US) 13th June 2024: Mursla Bio, a biotech company that is pioneering the way we diagnose and treat cancer, today announces that it has taken a significant strategic step by entering the US market and opening a new office in Cambridge, Massachusetts. This move marks an important milestone in establishing the company’s commercial and regulatory presence in support of its global customers.
Mursla…
Sign up to the Linkers System and receive email notifications
Access to new sales channels where leading manufacturers can directly access the database and engage with prospective partner companies.
What is Linkers?
Linkers is a system where SMEs, Startups and Academia can directly respond to the needs of major Japanese manufacturers.
Find out more via the hyperlink above!
Two companies, TraitSeq and PfBIO, that originated from research carried out at Norwich Research Park, have announced significant funding that will help them with the next stages of their development. Both were successful in securing grants of around £100,000 from Innovate UK’s Launchpad programme. Only seven companies in the East of England received these grants where the focus is to develop new activity in agri-tech and food technology and drive innovation in food production and sustainability.
TraitSeq has developed a technology that uses machine learning methods that ultimately enables…
T-Therapeutics appoints Dr David Hung as Chairman
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs
12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces the appointment of biopharma industry veteran Dr David Hung as Chairman of its Board of Directors.
Dr Hung is a hugely successful serial entrepreneur in the oncology space. He founded…
New space recognises the need for more cost-effective bench space and flexible agreements for startups and spinouts
Sandwich, Kent, UK / 10th June 2024 / Discovery Park, Kent’s thriving life science community, has opened the doors to CoLab, a new shared lab facility. In partnership with Canterbury Christ Church University, CoLab has been specially designed for early-stage life science businesses, providing flexible bench space in a collaborative coworking environment.
Dr Cornelia Wilson, Senior Lecturer and Academic Laboratory Director at Canterbury Christ Church University, said…
Your Local Laboratory For Rapid Whole Plasmid Nanopore Sequencing Results
Located in Cambridge, Source Genomics is a leading provider of genomic services, processing all samples within our UK laboratory. With the introduction of our new SpeedREAD™ data delivery system for Whole Plasmid Nanopore Sequencing, we now offer unrivaled turnaround times.
Why Choose SpeedREAD™?
Unmatched Speed: Receive high-quality Whole Plasmid Nanopore Sequencing data within 24 hours of sample receipt.
Streamlined Process: Our innovative SpeedREAD™ system ensures a seamless and efficient data retrieval experience.…
Milestone payment follows successful target identification and validation in separate project under same collaboration
Cambridge, UK, 03 June 2024: PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
PhoreMost and Boehringer Ingelheim entered a multi-project collaboration back in January 20201. In this second project, PhoreMost is…
CAMBRIDGE and NEWCASTLE, UK, 03 June 2024: DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.
In vitro liver models are laboratory-created liver cells or tissues that mimic the natural behaviour of…